These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 30843181)

  • 21. Medical treatment of acromegaly: comorbidities and their reversibility by somatostatin analogs.
    Tolis G; Angelopoulos NG; Katounda E; Rombopoulos G; Kaltzidou V; Kaltsas D; Protonotariou A; Lytras A
    Neuroendocrinology; 2006; 83(3-4):249-57. PubMed ID: 17047390
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Treatment of acromegaly.
    Holdaway IM
    Horm Res; 2004; 62 Suppl 3():79-92. PubMed ID: 15539805
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Acromegaly.
    Dineen R; Stewart PM; Sherlock M
    QJM; 2017 Jul; 110(7):411-420. PubMed ID: 26873451
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Impact of preoperative pasireotide therapy on invasive octreotide-resistant acromegaly.
    Yamamoto R; Robert Shima K; Igawa H; Kaikoi Y; Sasagawa Y; Hayashi Y; Inoshita N; Fukuoka H; Takahashi Y; Takamura T
    Endocr J; 2018 Oct; 65(10):1061-1067. PubMed ID: 30078825
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Current and future medical treatments for patients with acromegaly.
    Maffezzoni F; Formenti AM; Mazziotti G; Frara S; Giustina A
    Expert Opin Pharmacother; 2016 Aug; 17(12):1631-42. PubMed ID: 27352098
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Aftercare in patients with Cushing's disease and acromegaly: is there room for improvement?
    Psaras T; Milian M; Hattermann V; Gallwitz B; Freiman T; Honegger J
    Acta Neurochir (Wien); 2010 Feb; 152(2):271-8. PubMed ID: 19911113
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Acromegaly.
    Scacchi M; Cavagnini F
    Pituitary; 2006; 9(4):297-303. PubMed ID: 17077948
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Review of current and emerging treatment options in acromegaly.
    Muhammad A; van der Lely AJ; Neggers SJ
    Neth J Med; 2015 Oct; 73(8):362-7. PubMed ID: 26478545
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cotreatment of acromegaly with a somatostatin analog and a growth hormone receptor antagonist.
    Jørgensen JO; Feldt-Rasmussen U; Frystyk J; Chen JW; Kristensen LØ; Hagen C; Ørskov H
    J Clin Endocrinol Metab; 2005 Oct; 90(10):5627-31. PubMed ID: 16046586
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Resistant Paediatric Somatotropinomas due to AIP Mutations: Role of Pegvisomant.
    Joshi K; Daly AF; Beckers A; Zacharin M
    Horm Res Paediatr; 2018; 90(3):196-202. PubMed ID: 29953972
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy and Safety of switching to Pasireotide in Acromegaly Patients controlled with Pegvisomant and Somatostatin Analogues: PAPE extension study.
    Muhammad A; Coopmans EC; Delhanty PJD; Dallenga AHG; Haitsma IK; Janssen JAMJL; van der Lely AJ; Neggers SJCMM
    Eur J Endocrinol; 2018 Oct; 179(5):269-277. PubMed ID: 30076159
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pituitary tumor enlargement in two patients with acromegaly during pegvisomant therapy.
    Frohman LA; Bonert V
    Pituitary; 2007; 10(3):283-9. PubMed ID: 17534717
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Combined treatment of somatostatin analogues with pegvisomant in acromegaly.
    Franck SE; Muhammad A; van der Lely AJ; Neggers SJ
    Endocrine; 2016 May; 52(2):206-13. PubMed ID: 26661938
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cost-effectiveness analysis of second-line pharmacological treatment of acromegaly in Spain.
    Peral C; Cordido F; Gimeno-Ballester V; Mir N; Sánchez-Cenizo L; Rubio-Rodríguez D; Rubio-Terrés C
    Expert Rev Pharmacoecon Outcomes Res; 2020 Feb; 20(1):105-114. PubMed ID: 31055976
    [No Abstract]   [Full Text] [Related]  

  • 35. Improvement of cardiac parameters in patients with acromegaly treated with medical therapies.
    Colao A
    Pituitary; 2012 Mar; 15(1):50-8. PubMed ID: 21713528
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Treatment of acromegaly by endoscopic transsphenoidal surgery: surgical experience in 214 cases and cure rates according to current consensus criteria.
    Hazer DB; Işık S; Berker D; Güler S; Gürlek A; Yücel T; Berker M
    J Neurosurg; 2013 Dec; 119(6):1467-77. PubMed ID: 24074496
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Short-term pre-surgical treatment with somatostatin analogues, octreotide and lanreotide, in acromegaly.
    Waśko R; Ruchała M; Sawicka J; Kotwicka M; Liebert W; Sowiński J
    J Endocrinol Invest; 2000 Jan; 23(1):12-8. PubMed ID: 10698045
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Current treatment guidelines for acromegaly.
    Melmed S; Jackson I; Kleinberg D; Klibanski A
    J Clin Endocrinol Metab; 1998 Aug; 83(8):2646-52. PubMed ID: 9709926
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pharmacological therapy for acromegaly: a critical review.
    Muller AF; Van Der Lely AJ
    Drugs; 2004; 64(16):1817-38. PubMed ID: 15301564
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effects of previous growth hormone excess and current medical treatment for acromegaly on cognition.
    Brummelman P; Koerts J; Dullaart RP; van den Berg G; Tucha O; Wolffenbuttel BH; van Beek AP
    Eur J Clin Invest; 2012 Dec; 42(12):1317-24. PubMed ID: 23083406
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.